- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02723838
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) is a naturally occurring, ubiquitous, non-enveloped human reovirus. Reovirus has been shown to replicate selectively in Ras-transformed cells causing cell lysis. Activating mutations in Ras or mutations in oncogenes signaling through the Ras pathway may occur in as many as 80% of human tumors. The specificity of the reovirus for Ras-transformed cells, coupled with its relatively nonpathogenic nature in humans, makes it an attractive anti-cancer therapy candidate.
This is an open-label study of intratumoral REOLYSIN® in combination with standard of care neoadjuvant cisplatin/gemcitabine in patients with histologically and clinically confirmed muscle-invasive bladder cancer (T2-4) with or without pelvic lymph node involvement (N1-2) in Stage III and IV with no distant metastases (M0) and no prior systemic therapy for bladder cancer.
Treatment with intratumoral REOLYSIN® and chemotherapy is planned for 3 cycles followed by radical cystectomy or until unacceptable toxicity or another discontinuation criterion is met.
Two sequential treatment cohorts will be enrolled.
Patients in Cohort 1 will receive intratumoral REOLYSIN® on Cycle 1 Day 1, then 7-14 days later patients will receive intratumoral REOLYSIN® on Cycle 2 Day 1 plus intravenous neoadjuvant chemotherapy for 2 cycles (every 3 weeks) starting from Cycle 2 Day 2 followed by radical cystectomy. Three patients will be enrolled in this cohort. If there is a Dose Limiting Toxicity the cohort will be expanded to an additional 3 patients.
Upon completion of Cohort 1, Cohort 2 will be open to enrollment of 3 patients to receive 3 cycles of standard neoadjuvant chemotherapy on Day 1 and Day 8 of each cycle and intratumoral REOLYSIN® on Day 2 of each cycle (every 3 weeks). If there is a Dose Limiting Toxicity the cohort will be expanded to an additional 3 patients.
An Expansion Cohort will follow with up to 12 patients to be enrolled following either Cohort 1 or Cohort 2 treatment regimen based on the results of Cohort 1 and Cohort 2.
Tipo de estudio
Fase
- Fase 1
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Histologically and clinically confirmed muscle-invasive bladder cancer (T2-4) with or without pelvic lymph nodes involvement (N1-2) in Stage III and IV (M0).
- ECOG performance status ≤2.
- Adequate liver function with a bilirubin within normal limits. Transaminases up to 3 x ULN (Grade 1) and alkaline phosphatase may be up to 2.5 x ULN (Grade 1).
- Adequate bone marrow function, as defined by neutrophils count of ≥1,500/mm3, and platelet count ≥100,000/ mm3.
- Adequate renal function (serum creatinine ≤1.5 times the ULN).
- Negative pregnancy test and reliable and appropriate contraceptive method during the study for a woman of childbearing potential. All female patients of childbearing age and all male patients with partners of childbearing age should use a reliable method of contraception, such as the barrier method, throughout the study and for 60 days after last treatment.
- Informed of the investigational nature of this study and must sign a written informed consent in accordance with institutional and federal guidelines.
Exclusion Criteria:
- Received any prior therapy for invasive bladder cancer including surgery, radiation therapy, chemotherapy or any other systemic anti-cancer therapy (prior intravesical therapy for non-invasive bladder cancer is acceptable including intravesical BCG and/or mitomycin and interferon).
- Evidence of lymph nodes or other metastatic disease beyond the pelvis (N3 and/or M1).
- Pre-existing immunosuppressive or connective tissue disorders that require immune suppressive drugs.
- History of HIV or active hepatitis.
- Any serious concurrent illness including; but not limited to, unstable angina pectoris, uncompensated congestive cardiac failure; myocardial infarct in the previous 6 months; cardiac arrhythmias or psychiatric illness that would limit compliance with study requirements.
- Pregnant or lactating.
- A history of hypersensitivity to gemcitabine and cisplatin or any component of the formulation.
- A prior malignancy, other than non-melanoma skin cancer, unless they have completed therapy at least 5 years prior to start of study and have no evidence of recurrent or residual disease.
- Unwilling or unable to sign informed consent document.
- In social situations that would limit compliance with study requirements.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Periodo de tiempo: During treatment and up to 28 days after treatment
|
Nature, frequency, severity and timing of Adverse Events.
|
During treatment and up to 28 days after treatment
|
Pre- and post-treatment biopsies will be evaluated for tumor viability, percentage of necrosis, reovirus replication and tumor infiltration of immune cells and expression of PD-1 and PD-L1
Periodo de tiempo: Assessed at surgery conducted following 3 3-week study treatment cycles
|
Assessed at surgery conducted following 3 3-week study treatment cycles
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Time to Treatment Failure (TTF)
Periodo de tiempo: By medical chart review until disease reoccurrence or 2 years from surgery, whichever occurs first first.
|
By medical chart review until disease reoccurrence or 2 years from surgery, whichever occurs first first.
|
Disease Free Survival (DFS)
Periodo de tiempo: By medical chart review until disease reoccurrence or death or 2 years from surgery, whichever occurs first.
|
By medical chart review until disease reoccurrence or death or 2 years from surgery, whichever occurs first.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias Urológicas
- Neoplasias urogenitales
- Neoplasias por sitio
- Enfermedades urológicas
- Neoplasias Glandulares y Epiteliales
- Enfermedades de la vejiga urinaria
- Carcinoma
- Neoplasias de la vejiga urinaria
- Carcinoma De Células De Transición
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Gemcitabina
Otros números de identificación del estudio
- REO 023
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre REOLYSIN®
-
Oncolytics BiotechTerminadoOsteosarcoma | Leiomiosarcoma | Fibrosarcoma | Sarcoma Sinovial | Tumores de la familia del sarcoma de Ewing | Histiocitoma fibroso malignoEstados Unidos
-
Oncolytics BiotechTerminadoGlioma malignoEstados Unidos
-
Oncolytics BiotechTerminadoCarcinoma de Células Escamosas de Cabeza y CuelloEstados Unidos
-
Oncolytics BiotechTerminadoCarcinoma de pulmón de células no pequeñasEstados Unidos
-
Oncolytics BiotechTerminadoAdenocarcinoma de páncreasEstados Unidos
-
Oncolytics BiotechSOLTI Breast Cancer Research GroupTerminado
-
Canadian Cancer Trials GroupOncolytics BiotechTerminadoCáncer de pulmón de células no pequeñasCanadá
-
Oncolytics BiotechMontefiore Medical CenterTerminadoCáncer colorrectal metastásico mutante KRASEstados Unidos
-
Dong-A ST Co., Ltd.TerminadoDispepsia funcionalCorea, república de
-
Chung-Ang University Hosptial, Chung-Ang University...DesconocidoDispepsia funcionalCorea, república de